In our study, we found that routine screening at the first assessment during Phase 2 CRP indicates that nearly 20% and 30% of the cohort potentially may present with significant depression and anxiety symptoms based on PHQ-2 and GAD-2 scores, respectively. This evidence concerns the gene CRP and Anxiety.